Some links on our site may earn us a commission at no extra cost to you. Learn more.
Medical Disclaimer: We are not doctors or medical professionals, and nothing on this page is medical advice. This article is for general informational purposes only. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider, and they are not appropriate for everyone. Always consult a qualified clinician before starting, stopping, or changing any medication or weight loss program.
Hims is the most recognizable name in consumer telehealth, and its weight loss program is one of the most searched GLP-1 options in the country. It’s also a program that changed fundamentally in 2026 — so much of what you may have read about “cheap compounded semaglutide from Hims” is now out of date. Here’s an accurate, current picture of what Hims weight loss actually is, what it costs, and who it fits.
The big change: Hims after the Novo Nordisk settlement
Through 2024–2025, Hims was one of the largest sellers of compounded semaglutide in the US. That era ended: following a public dispute over aggressive compounded pricing, Hims and Novo Nordisk (maker of Ozempic® and Wegovy®) reached a settlement in March 2026, and Hims wound down compounded semaglutide for new patients. Today’s Hims weight loss program is built around brand-name, FDA-approved medications — a genuinely important distinction in a market where most budget telehealth platforms sell compounded products that are not FDA-approved.
What the program offers now
According to Hims’ published materials as of mid-2026, the current lineup centers on brand-name GLP-1s, including Wegovy® (injectable and the newer oral pill form) and access to tirzepatide-based options such as Zepbound® routed through the manufacturer’s direct channel, with eligibility determined by a licensed provider. The clinical model is fully online and asynchronous: you complete an intake, a licensed clinician reviews it (typically no video visit and no required lab work), and if appropriate, treatment is prescribed with ongoing messaging support through the Hims app.
The pricing structure — read this part twice
Hims pricing has two components, and conflating them is the most common source of sticker shock in user reviews:
- The Weight Loss Membership: per Hims’ own site, $39 for the first month, auto-renewing at $149/month thereafter — billed separately, required to access medication, and (their words) it does not include or guarantee a prescription.
- The medication itself: reported pricing as of mid-2026 runs roughly $249/month for oral Wegovy, $299/month for Wegovy injectable, and $399/month for Zepbound for self-pay patients — on top of the membership.
Prices are approximate, current as of publication, and change frequently — confirm the latest price with the retailer before buying.
That makes the realistic self-pay total meaningfully higher than the headline number — plan on medication plus membership when you budget. Prices in this industry change constantly, so verify current figures on Hims’ official site before enrolling.
The insurance angle — Hims’ quietest advantage
Here’s where the brand-name pivot pays off: because Hims now dispenses FDA-approved products, commercial insurance and manufacturer savings programs can apply. Reports indicate that eligible patients with commercial insurance using the Novo Nordisk savings card can bring brand-name Wegovy down to as little as $0–$25/month through Hims — a route that simply doesn’t exist for compounded programs, which are cash-pay by nature. If you have commercial coverage, this single fact can make Hims one of the cheapest legitimate options on the market; if you don’t, it’s one of the pricier ones. (Government plans like Medicare/Medicaid are typically excluded from such savings cards.)
The honest caveats
- Light-touch clinical model. Asynchronous messaging only, no required labs, no obesity-medicine specialists — reviewers consistently place Hims at the convenience end of the clinical-depth spectrum. Fine for straightforward cases; a poor fit for complex medical histories, by the platform’s own design.
- The membership fee math. $149/month for the care wrapper is real money that comparison shoppers should weigh against all-inclusive competitors.
- A regulatory footnote. In September 2025, the FDA issued Hims & Hers a warning letter over marketing language for its then-compounded products — specifically, comparisons implying equivalence to brand-name drugs. It concerned marketing claims rather than product safety, and the compounded program at issue has since been wound down, but it’s part of the company’s record and worth knowing.
- Prescription isn’t guaranteed. As with every telehealth program, a licensed provider decides — the membership buys evaluation and support, not a guaranteed outcome.
Who Hims fits
A strong fit if: you specifically want FDA-approved brand-name medication rather than compounded alternatives; you have commercial insurance that can combine with manufacturer savings; or you value a household-name, publicly traded company over lower-cost unknowns.
Look elsewhere if: you’re cash-pay and budget-first (compounded-focused programs like TrimRX or Wellorithm publish far lower entry prices — see our TrimRX review and Wellorithm review); you want hands-on clinical monitoring, labs, and structured coaching; or the two-line pricing structure bothers you on principle.
Bottom line
Post-settlement Hims is a different — and in some ways more trustworthy — product than the one that made headlines: FDA-approved medications, a mainstream brand, and a real insurance pathway, traded against a stacked pricing structure and a deliberately minimal clinical model. Run the two-component math for your situation, check your insurance eligibility first, and as always, start with a conversation with a licensed healthcare provider about whether GLP-1 treatment belongs in your plan at all.
Program details, pricing, and terms described here are based on publicly available information as of mid-2026 and change frequently — verify everything on the provider’s official website. Ozempic®, Wegovy®, Zepbound®, and Mounjaro® are trademarks of their respective owners, which are not affiliated with this site.
